STAT+: Here’s why there aren’t many cheap, generic versions of pricey inhalers
STAT News
MARCH 16, 2023
regulators approved dozens of inhalers to treat asthma and chronic obstructive pulmonary disease over a recent 15-year period, but a new study found that generic companies have only twice successfully pursued an established pathway to create lower-cost, rival products. Continue to STAT+ to read the full story…
Let's personalize your content